AnHorn Medicines is a novel drug discovery company with a strong pipeline, offering therapies that target and degrade disease-related proteins. Our mission is to develop new class of drugs BIGPRO® (Bi-functional liGand induced PROteolysis) under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.
We focus on novel therapies for cancer, neurodegeneration, and aging diseases by applying AnHorn’s proprietary AIMCADD®, an AI-enabled platform screening high potential drug candidates. We are turning innovation into new therapeutics – new opportunities to target difficult-to-treat diseases and diseases plagued by drug resistance.
Our proprietary BIGPRO® protein degrader gives precise elimination of diseased protein that helps the human body to return to a healthy state.
Our founder Dr. CC Lin and his team have built on groundbreaking AIMCADD® platform (Artificial intelligence-Bioinformation-Medicinal chemistry-Computer-Aid Drug Design), which is a knowledge base of drug discovery expertise that generates successful candidates with efficiency. Our mission is to unlock the full potential of BIGPRO® protein degradation by developing our robust pipeline and by partnering with the world’s leading drug development companies.
• Develop extensive BIGPRO® pipeline at early drug development stages.
• Go beyond next generation of Targeted Protein Degradation by developing novel E3 ligases with effective binder.
• Extending the portfolio to the rest 80% novel targets for treatments of cancer, neurodegenerative, and age-related diseases.
• Establishing an extensive and multi-layered patent portfolio to protect our technologies and product candidates.
Dr. Lin Chu-Chiang has more than 25 years of experience in a range of strategic and operating roles in the biotechnology sector specializing in pharmaceutical research and management. Dr. Lin is one of the top scientists in Taiwan who possess a complete range of new drug research and development, including target selection, computer-aided drug design, drug development, patent protection, CMC process development, quality management, clinical trial drug supply, in-licensing and out-licensing, and new drug approval.
Prior to AnHorn Medicines, Dr. Lin served at TaiGen Biotechnology for nearly 20 years as director, senior director, and vice president of R&D. He led the research and development team on antiviral and antibiotic new drug programs, developed several drug candidates into clinical stage and out-licensing. In 1998, he joined the first new drug development team in Taiwan at the National Health Research Institutes; he was responsible for the development of anticancer drugs. Dr. Lin is one of the top scientists who possess track record of realizing the intellectual property value of new drug discovery.
Dr. Lin holds Ph.D. from the Department of Applied Chemistry at National Chiao Tung University. He has published 28 academic papers and owns more than 80 patents. In 2016, he led the TaiGen Biotechnology team to receive the Chemical Technology Medal from the Chinese Chemical Society.
Dr. Lin Chu-Chiang
Founder and President
Board of Directors
Lin Chu-Chiang, Ph.D.
Founder and President
Dr. Lin Chu-Chiang is the President of the board and the founder of AnHorn Medicines. He has more than 25 years of experience in a range of strategic and operating roles in the biotechnology sector specializing in pharmaceutical research and management. He served at the National Health Research Institutes and TaiGen Biotechnology, leading chemistry teams to develop First-in-class and Best-in-class small molecule drugs. In his previous tenure, the primary focused therapeutic areas include cancer, and anti-infective drugs (antibiotics and antivirals); and now the primary focus of AnHorn Medicines is in protein degradation for various diseases.
Jo Shen, Ph.D.
Jo Shen was the co-founder of ScinoPharm Pharmaceutical, and currently she is the venture partner of Vivo Capital. She is an international pharmaceutical executive with more than 40 years of experience in the industry.
Dr. Shen has a rounded experiences in drug manufacturing and development. She held executive positions in several leading multinational GMP drug manufacturing companies where she manages business development, product marketing, team building, corporate strategic planning, and investor relations. She currently serves on a number of boards including Taiwan Bio Industry Organization and multiple Taiwan pharmaceutical and biotech companies.
Dr. Shen will provide the guidance and support to the company from the topic of corporate strategies, business development, and technology transfer, to meet the needs of a corporate development in different stages.
Bryan Kao, Ph.D.
Director representing Taiwania Capital
Dr. Kao is the Senior Investment Manager at Taiwainia Capital Biofund Venture. He has solid international private investment experience in the biotech industry across US and Taiwan. Dr. Kao has evaluated and invested in protein degradation new drug discovery company in US, so he believes in a great potential in the field. Prior to Taiwania Capital, Dr. Kao was the research scientist in the new drug development of small molecules in immune-oncology and regenerative medicine. During the time, he managed the drug market analysis, biology research, clinical trial design, new drug registration application, and sales strategy.
Dr. Kao will assist the company with business strategy and establishing connections with international venture capital.